Member Info for Polio

Yeehaaaa

Far too many worrying about this, the drop is because people can buy at 9.5p on the retail offer. It will stay here until that is completed

Lets goooooo

And as soon as real people start seeing results this will explode

Agree - IMM and HEMO are making zero to little revenue but we are now and have something massive.

Presentation is up - look at those potentials

Exceeding 20% target of last year

Estimated revenue potential in NY $754 mill

Texas - $1.3 billion

Florida - $921 mil

https://investors.renalytix.com/presentations/.

I was expecting a higher increase in revenue to be honest or have I missed something ?

Investor Presentation and Revised Revenue Guidance

Revised forward guidance on expected long-term increase in revenue

LONDON and NEW YORK, 23 September 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that an updated corporate presentation will be available today for download from the Company's website at https://investors.renalytix.com/presentations/.

The corporate presentation includes revised forward guidance on the Company's expected revenue: $8.4m in FY26, $19.0m in FY27 and $42.0m in FY28 with the later years of FY27 and FY28 reflecting the anticipated positive revenue impact from Renalytix's recently announced collaboration agreement with Tempus AI, Inc. (Nasdaq: TEM) ("Tempus"). This revenue guidance compares to a prior outlook through FY27 calling for $8.5m in FY26, and $17.5m for FY27 as provided in the Company's Half Year Report on 18 March 2025.

The Board of Directors are currently considering the long-term positive impact of the Tempus collaboration and the Company will provide further updates regarding forward revenue guidance as appropriate, as the two parties execute implementation into hospital systems and other healthcare providers.

For further information, please contact:

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Tel: +44 (0)20 3470 0470

Jeff Keating / David Hignell (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Oberon Capital (Joint Broker)

Tel: +44 (0)20 3179 5300

Mike Seabrook / Nick Lovering / Aimee McCusker

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Alice Woodings

Mob: 07980 541 893 / 07407 804 654

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in selec

Nice

RnS - HOLY cow, all raised in a day?

9.5 is the benchmark now

Why are a few of you worries because we have seen a bit of red. Don't look at the day to day!

This will go bananas at some point, we have all the information we need. Just chill and enjoy the ride

3 million in here Marty? lol okkkkkk

Now then!! Some decent buys

Anyone de ramping this company needs a straight jacket. We have everything in place, we now have funds and we have a collaboration with a company valued at $1.5 billion where the CEO posted on his linked in last week!

Onwards and upwards

The very bottom is now 9.5p lets go

More than happy with that, they are raising above my average. Now let the fun begin!

Yes you will duster

The crazy thing is that it’s not fully 1 bagged from the 52 Week Low a few weeks back!!

What a great find thank you

The best healthcare AI gives doctors superpowers without the complexity.

Five years ago, our partnerships were simple: Share data. Build algorithms. Plan for adoption later.

Today? The AI game has completely shifted to distribution into clinical workflows.

The brutal truth about chronic kidney disease:

• 15 million Americans have diabetic kidney disease

• 90% patients don't even know they have it

• Medicare spends $130 billion annually cleaning up the aftermath

This isn't just market opportunity. It's a silent epidemic.

[Enter Renalytix] FDA-approved test. Medicare reimbursed. Predicts kidney disease progression in diabetic patients.

But here's what stopped me in my tracks about them:

They weren't pitching their algorithm's accuracy. They were obsessing over physician workflow integration.

That's when I knew we had to work together.

Today, Tempus AI announced our collaboration with Renalytix and its kidneyintelX.dkd test to become the first chronic kidney disease test in our portfolio.

𝗪𝗵𝗮𝘁 𝘄𝗲 𝗹𝗲𝗮𝗿𝗻𝗲𝗱 𝗮𝗯𝗼𝘂𝘁 𝘀𝗰𝗮𝗹𝗶𝗻𝗴 𝗔𝗜-𝗲𝗻𝗮𝗯𝗹𝗲𝗱 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀

At Tempus AI, we've seen brilliant diagnostic algorithms struggle to find their footing in clinical practice.

The pattern is always the same: Amazing accuracy in controlled studies ✓ Regulatory approval ✓ Reimbursement pathway ✓ Clinical workflow integration... ❌

Renalytix cracked this code.

Their test doesn't just predict risk levels—it delivers actionable insights directly into existing clinical workflows.

𝗙𝗼𝗿 𝗼𝘁𝗵𝗲𝗿 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝗜 𝗹𝗲𝗮𝗱𝗲𝗿𝘀: The question isn't whether your algorithm is accurate enough.

The question is: Can your solution fit seamlessly into a Tuesday afternoon clinic when the physician is running behind and has six more patients to see?

𝗪𝗵𝗮𝘁 𝗜 𝘄𝗶𝘀𝗵 𝗺𝗼𝗿𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗔𝗜 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗼𝗼𝗱: the best algorithms don’t always win. Solutions that can solve workflow problems effortlessly make all the difference.

𝘞𝘩𝘢𝘵'𝘴 𝘣𝘦𝘦𝘯 𝘺𝘰𝘶𝘳 𝘦𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦 𝘴𝘤𝘢𝘭𝘪𝘯𝘨 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴? 𝘞𝘩𝘦𝘳𝘦 𝘥𝘰 𝘺𝘰𝘶 𝘴𝘦𝘦 𝘵𝘩𝘦 𝘣𝘪𝘨𝘨𝘦𝘴𝘵 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘪𝘦𝘴 𝘧𝘰𝘳 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘤 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱𝘴?

The chronic disease space is massive and underserved. Let's solve this together.

Comek2 we aren’t the same business as the two you have mentioned, let’s enjoy our own journey